<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02067806</url>
  </required_header>
  <id_info>
    <org_study_id>CHL1/01-2012/M</org_study_id>
    <nct_id>NCT02067806</nct_id>
  </id_info>
  <brief_title>Observational Study on 2-chloroprocaine Hydrochloride 1%</brief_title>
  <acronym>PASS</acronym>
  <official_title>Observational Prospective Study on 2-chloroprocaine Hydrochloride 1% Safety in Intrathecal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sintetica SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sintesi Research Srl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sintetica SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to evaluate the relationship between spinal block with 1% solution of&#xD;
      2-chloroprocaine hydrochloride and the onset of all possible neurological adverse events,&#xD;
      with particular attention to Transient Neurological Symptoms (TNS) and Cauda Equina Syndrome&#xD;
      (CES).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint :Incidence of neurological complications (Transient and Permanent&#xD;
      complications; e.g. transient neurological symptoms, arachnoiditis, cauda equina&#xD;
      syndrome).Two follow-up questionnaires are foreseen, at 24 h and 7 days after time of spinal&#xD;
      injection (Tsp), to gather all possible neurological complications, with particular attention&#xD;
      to Transient Neurological Symptoms (TNS) and Cauda Equina Syndrome (CES).Patients scheduled&#xD;
      for elective surgery will be informed about the aims, procedures and possible risks of the&#xD;
      study and will be asked to sign the informed consent form for the inclusion in the trial,&#xD;
      from day -14 to day of surgery (visit 1, Day 0).This observational study is planned to&#xD;
      collect data on patients undergoing surgery under intrathecal anesthesia with chloroprocaine&#xD;
      hydrochloride, primarily to assess the occurrence of all possible neurological adverse events&#xD;
      (with particular attention to TNS and CES). The mandatory follow-ups of the study are at 24 h&#xD;
      and 7 days (-1/+2) after anaesthesia. In case of signs of neurological complications, the&#xD;
      patient has to undergo to a medical visit at the hospital by the relevant specialists&#xD;
      (anaesthetist, surgeon, neurologist). In order to characterise the occurred adverse event, a&#xD;
      complete analysis evaluation has to be conducted, as CT, MRI, Electromyography, etc.&#xD;
      following the indication of the specialists. In case of persistent neuropathy the patient&#xD;
      needs to be accurately followed according to the internal hospital procedure. In the&#xD;
      meantime, a full screening of the patient's clinical history together with a detailed&#xD;
      analysis of the relevant variables, potentially related to the adverse event, have to be&#xD;
      carried out.&#xD;
&#xD;
      Therefore, the physician will take all appropriate measures to ensure the safety of the&#xD;
      patients, notably he/she should follow up the outcome of any Adverse Events (clinical signs,&#xD;
      laboratory values or other, etc.) until the return to normal or consolidation of the&#xD;
      patient's condition. In case of any Serious Adverse Event, the patient has to be followed up&#xD;
      until clinical recovery is complete and laboratory results have returned to normal, or until&#xD;
      progression has been stabilized. The follow-up will continue after the patient has left the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>assessed at 24h and 7(-1/+2) days after surgery, total reported</time_frame>
    <description>Number of Participants with neurological adverse events, with particular attention to Transient Neurological Symptoms (TNS) and Cauda Equina Syndrome(CES).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Symptoms in Follow-Up Questionnaire at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>the follow-up questionnaires are foreseen, at 24 h after time of spinal injection (Tsp), to gather all possible neurological adverse events. About 24 h after surgery (indicated as Tsp),Investigator or a deputy will question patients about neurological symptoms and pain not associated to the operation area on the basis of the follow-up questionnaires and giving a score between 0 to 10 to the pain intensity. All other adverse events will also be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Symptoms in Follow-Up Questionnaire at 7 Days</measure>
    <time_frame>7 days</time_frame>
    <description>the follow-up questionnaires are foreseen, at 7 days after time of spinal injection (Tsp), to gather all possible neurological adverse events. About 7 days after surgery (indicated as Tsp),Investigator or a deputy will question patients about neurological symptoms and pain not associated to the operation area on the basis of the follow-up questionnaires and giving a score between 0 to 10 to the pain intensity. All other adverse events will also be assessed.</description>
  </primary_outcome>
  <enrollment type="Actual">394</enrollment>
  <condition>Neurological Complication, in Particular TNS or CES</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-chloroprocaine hydrochloride, 1%</intervention_name>
    <description>Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.</description>
    <other_name>Ampres 1%</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for elective surgery will be informed about the aims, procedures and&#xD;
        possible risks of the study and will be asked to sign the informed consent form for the&#xD;
        inclusion in the trial, from day -14 to day of surgery (visit 1, Day 0).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/female adult patients&#xD;
&#xD;
          -  Ability to comprehend the full nature and purpose of the study&#xD;
&#xD;
          -  Ability to co-operate with the Investigator and to comply with the requirements of the&#xD;
             entire study&#xD;
&#xD;
          -  Signed written informed consent of the patients prior to inclusion in the&#xD;
             observational study. The signature has to be done before the elective surgery.&#xD;
&#xD;
          -  Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40&#xD;
             minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to the active substance, medicinal products of the PABA&#xD;
             (para-aminobenzoic acid) ester group, other ester-type local anaesthetics or to any of&#xD;
             the excipients (Hydrochloric acid 1N for pH adjustment, Sodium chloride, Water for&#xD;
             injection)&#xD;
&#xD;
          -  General and specific contra-indications to spinal anaesthesia regardless of the local&#xD;
             anaesthetic used, should be taken into account (e.g. decompensated cardiac&#xD;
             insufficiency, hypovolemic shockâ€¦.)&#xD;
&#xD;
          -  Intravenous regional anaesthesia (the anesthetic agent is introduced into the limb and&#xD;
             allowed to set in while tourniquets retain the agent within the desired area)&#xD;
&#xD;
          -  Serious problems with cardiac conduction,&#xD;
&#xD;
          -  Severe anaemia,&#xD;
&#xD;
          -  It is also necessary to take into consideration general and specific contraindications&#xD;
             for the technique of spinal anaesthesia = intrathecal anaesthesia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Fanelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera di Parma Dipartimento di Anestesia, Rianimazione e Terapia Antalgica - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Capdevila Xavier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Department of Anesthesiology and Critical Care Medicine of Lapeyronie, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Bonarelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rizzoli Hospital, Bologna - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Van Delft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Critical Care Medicine, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holger Sauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik fÃ¼r AnÃ¤sthesie, Intensivmedizin und Schmerztherapie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik fÃ¼r AnÃ¤sthesiologie, Intensiv-, Palliativ- und Schmerzmedizin Berufsgenossenschaftliches</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Delaunay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique gÃ©nÃ©rale d'Annency - La consultation d'AnesthÃ©sie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Critical Care Medicine-Hospital AZ Sint Jozef</name>
      <address>
        <city>Malle</city>
        <zip>2390</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <results_first_submitted>May 6, 2021</results_first_submitted>
  <results_first_submitted_qc>June 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PASS</keyword>
  <keyword>TNS</keyword>
  <keyword>CES</keyword>
  <keyword>CHLOROPROCAINE</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroprocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chloroprocaine 1%</title>
          <description>Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="394"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chloroprocaine 1%</title>
          <description>intrathecal anesthesia with 1% solution of 2-chloroprocaine hydrochloride in patients undergoing short surgical procedures (max. 40 minutes).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="393"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="388"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of Participants with neurological adverse events, with particular attention to Transient Neurological Symptoms (TNS) and Cauda Equina Syndrome(CES).</description>
        <time_frame>assessed at 24h and 7(-1/+2) days after surgery, total reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine 1%</title>
            <description>Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of Participants with neurological adverse events, with particular attention to Transient Neurological Symptoms (TNS) and Cauda Equina Syndrome(CES).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Symptoms in Follow-Up Questionnaire at 24 Hours</title>
        <description>the follow-up questionnaires are foreseen, at 24 h after time of spinal injection (Tsp), to gather all possible neurological adverse events. About 24 h after surgery (indicated as Tsp),Investigator or a deputy will question patients about neurological symptoms and pain not associated to the operation area on the basis of the follow-up questionnaires and giving a score between 0 to 10 to the pain intensity. All other adverse events will also be assessed.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine 1%</title>
            <description>intrathecal anesthesia with 1% solution of 2-chloroprocaine hydrochloride in patients undergoing short surgical procedures (max. 40 minutes).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptoms in Follow-Up Questionnaire at 24 Hours</title>
          <description>the follow-up questionnaires are foreseen, at 24 h after time of spinal injection (Tsp), to gather all possible neurological adverse events. About 24 h after surgery (indicated as Tsp),Investigator or a deputy will question patients about neurological symptoms and pain not associated to the operation area on the basis of the follow-up questionnaires and giving a score between 0 to 10 to the pain intensity. All other adverse events will also be assessed.</description>
          <units>number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>urin/defec problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Symptoms in Follow-Up Questionnaire at 7 Days</title>
        <description>the follow-up questionnaires are foreseen, at 7 days after time of spinal injection (Tsp), to gather all possible neurological adverse events. About 7 days after surgery (indicated as Tsp),Investigator or a deputy will question patients about neurological symptoms and pain not associated to the operation area on the basis of the follow-up questionnaires and giving a score between 0 to 10 to the pain intensity. All other adverse events will also be assessed.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine 1%</title>
            <description>intrathecal anesthesia with 1% solution of 2-chloroprocaine hydrochloride in patients undergoing short surgical procedures (max. 40 minutes).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptoms in Follow-Up Questionnaire at 7 Days</title>
          <description>the follow-up questionnaires are foreseen, at 7 days after time of spinal injection (Tsp), to gather all possible neurological adverse events. About 7 days after surgery (indicated as Tsp),Investigator or a deputy will question patients about neurological symptoms and pain not associated to the operation area on the basis of the follow-up questionnaires and giving a score between 0 to 10 to the pain intensity. All other adverse events will also be assessed.</description>
          <units>number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>urin/defec problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chloroprocaine 1%</title>
          <description>Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>drug effect incomplete</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>drug ineffective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>anesthetic complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>incision site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>hypotonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hyprventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Elisabetta Donati, Corporate Director Scientific Affairs</name_or_title>
      <organization>Sintetica SA</organization>
      <phone>+41.91.640.42.50</phone>
      <email>edonati@sintetica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

